Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.

[1]  Ying Cheng,et al.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. , 2018, The Lancet. Oncology.

[2]  B. Han,et al.  EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. , 2017, Lung cancer.

[3]  Y. Ung,et al.  Postoperative Adjuvant Systemic Therapy in Completely Resected Non–Small‐Cell Lung Cancer: A Systematic Review , 2017, Clinical lung cancer.

[4]  R. Shah.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas , 2016, Drug Safety.

[5]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[6]  Yunpeng Liu,et al.  Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study , 2015, PloS one.

[7]  B. Han,et al.  First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Chun-Ming Tsai,et al.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Kris,et al.  Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. , 2015, The Cochrane database of systematic reviews.

[10]  R. Rosell,et al.  Interstitial lung disease arising from erlotinib treatment in a Caucasian patient. , 2015, Clinical Lung Cancer.

[11]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[12]  M. Kris,et al.  SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. , 2014 .

[13]  Ning Li,et al.  Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study , 2014, Annals of Surgical Oncology.

[14]  L. Tong,et al.  Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. , 2013, Lung cancer.

[15]  J. Remon,et al.  Adjuvant treatment in resected non-small cell lung cancer: current and future issues. , 2013, Critical reviews in oncology/hematology.

[16]  J. Jett,et al.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Héon,et al.  Adjuvant chemotherapy for surgically resected non-small cell lung cancer. , 2012, The Journal of thoracic and cardiovascular surgery.

[18]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[19]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[20]  W. Ou,et al.  Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[22]  H. Wakelee,et al.  Adjuvant chemotherapy for resected non-small cell lung cancer. , 2008, Seminars in thoracic and cardiovascular surgery.

[23]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[25]  R. Rami-Porta,et al.  Complete resection in lung cancer surgery: proposed definition. , 2005, Lung cancer.

[26]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[27]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.